MCRB — Seres Therapeutics, Inc.
$1.40
$-0.01 (-0.71%)
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Market Cap
$14.27M
Forward P/E
-0.7x
52-Week Range
N/A
MCRB Price History
Revenue vs. Net Income
$789K
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$865K
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
4.8%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.5x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
31.9%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+14.2%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
